Taiwan-based Formosa Pharmaceuticals (6838.TW) has signed an exclusive licensing agreement with Apotex Inc., granting the Canadian pharmaceutical company commercialization rights in Mexico for its newly approved ophthalmic drug, clobetasol propionate ophthalmic suspension, 0.05% (APP13007).
APP13007, approved by the U.S. Food and Drug Administration (FDA) in 2024, is designed to relieve inflammation and pain following eye surgery. The drug contains clobetasol propionate, a powerful corticosteroid, and is formulated using Formosa’s patented APNT® nanoparticle platform. This formulation allows for an easy-to-follow dosing schedule and delivers rapid and long-lasting relief. In Phase 3 clinical trials, the treatment significantly outperformed a placebo, showing both statistical and clinical superiority (p<0.001).
Formosa CEO Erick Co expressed optimism about expanding the company’s partnership with Apotex. “We are pleased to extend our collaboration with Apotex to include Mexico,” said Co. “Their Canadian team’s strong dedication to high-quality ophthalmic products gives us full confidence that APP13007 will quickly reach patients and doctors in Mexico.”
Apotex International President Alok Kanti emphasized the company’s focus on improving patient access. “We’re committed to making innovative health solutions available and are excited to bring APP13007 to Mexico upon regulatory approval,” he said. “This agreement reinforces Apotex’s leadership in pharmaceutical licensing across the Americas.”
APP13007’s entry into Mexico marks another milestone in Formosa and Apotex’s shared strategy to expand access to advanced, branded eye treatments across global markets.
Related topics:
